Securities Code: 301584 Securities Abbreviation: Ever-Growth New Medical Announcement No.: 2026-020
Shanghai Ever-Growth New Medical Technology Group Co., Ltd. Announcement on Confirmation of 2025 Remuneration and 2026 Remuneration Plan for Directors and Senior Management
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, complete, and free from false records, misleading statements, or material omissions.
In accordance with the "Company Law of the People's Republic of China," "Guiding Principles for Listed Companies," and other laws and regulations, as well as the "Articles of Association of Shanghai Ever-Growth New Medical Technology Group Co., Ltd." and the "Remuneration Management System for Directors and Senior Management," the Company convened the 14th meeting of the Third Board of Directors on April 17, 2026, and reviewed the "Proposal on Confirmation of 2025 Remuneration and 2026 Remuneration Plan for Directors and Senior Management of the Company."
Specifically, the proposal for the confirmation of 2025 remuneration and the 2026 remuneration plan for the Company's directors was directly submitted to the Company's 2025 Annual Shareholders' Meeting for deliberation due to all directors abstaining from voting. The proposal for the confirmation of 2025 remuneration and the 2026 remuneration plan for the Company's senior management was deliberated and approved by the Board of Directors, with related directors Mr. Wu Shengyong and Mr. Wang Jianxin abstaining from voting.
The confirmation of 2025 remuneration and the 2026 remuneration plan for the Company's directors and senior management are hereby announced as follows:
I. Confirmation of 2025 Remuneration for Directors and Senior Management
After calculation, the remuneration for the Company's directors and senior management in 2025 is as follows: